secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001528287-22-000026
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace Q3 revenue $11.2M (+8% YoY); lifts FY revenue guidance to $44.5-45.5M
-------------------------------------------------------------------------------

- Initial implant revenue $9.2M (+18% YoY); replacement revenue $1.9M vs $2.5M prior year.
- Net loss $11.8M vs $8.1M prior year; operating expenses $18.2M vs $13.8M.
- Cash and equivalents $85.4M, down from $92.4M at June 30; long-term debt $52.0M.
- Gross margin 71% vs 73% due to short-term supply chain disruption, now resolved.
- Initiated distribution of DIXI Medical stereo EEG electrodes on Oct 1, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000152828722000026/0001528287-22-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000152828722000026/npce-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001528287-22-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer